Figure 6.

ARRY attenuates progression of lung fibrosis. (A) Representative photomicrographs of lung tissues for each group stained with H&E and taken at 10× magnification. Upper panel shows the area of airways, vessels, and parenchyma of the lung. Lower panel shows the pleural regions of the lung. Scale bar, 200 μm. (B) ARRY administered 4 weeks after the initiation of TGF-α induction demonstrated attenuation of transcripts for extracellular matrix genes, col1a, col3a, and col5a. Real-time PCR analysis was performed using total lung RNA isolated from the lungs. Data are means (±SEM) (n = 4/group). (C) ARRY administered 4 weeks after the initiation of TGF-α induction demonstrated no change in total lung collagen compared with vehicle-treated mice. Data are means (±SEM) (n = 7–9/group). (D) ARRY prevents progression of TGF-α–dependent changes in lung mechanics. CCSP/TGF-α transgenic mice administered ARRY 4 weeks after treatment with Dox demonstrated reduced increases in airway resistance and compliance as compared with vehicle-treated CCSP/TGF-α transgenic mice receiving 8 weeks of Dox. Data are means (±SEM) and statistical significance between groups was measured using one-way ANOVA (n = 7–9/group).